Sapphire Biotech
  • Home
  • Science
  • Our Team
  • Press
  • Contact
Select Page
Biotech Professionals Express Fears…and Hope, During Pandemic

Biotech Professionals Express Fears…and Hope, During Pandemic

by admin | May 5, 2020 | Press

The fourth-most mentioned fear (at 14%) was a resurgence or a spike in infections after restrictions are lifted. Much about the SARS-CoV-2 virus is still being discovered. “Our biggest fear regarding the pandemic is that there will be future waves of outbreaks until...
Clinical Trial Begins Using Sapphire Biotech’s Lateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer

Clinical Trial Begins Using Sapphire Biotech’s Lateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer

by admin | Dec 20, 2019 | Press

Sapphire Biotech scientists have developed a new lateral flow assay test to measure the enzyme QSOX1 that is found to be elevated in subjects with pancreatic cancers. The purpose of the trial is to evaluate the diagnostic potential of Sapphire’s lateral flow assay to...
Clinical Trial Begins Using Sapphire Biotech’s Lateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer

Sapphire Biotech Files for Small Business Investigational Research Grant to Develop Compounds That Target Metastasis

by admin | Sep 5, 2019 | Press

Sapphire Biotech has filed for a Small Business Investigational Research (SBIR) grant to develop potent and soluble analogs of SBI-183, a compound that has been shown to inhibit tumor growth and metastasis. The SBIR would fund Sapphire’s scientists’ ongoing research...
Clinical Trial Begins Using Sapphire Biotech’s Lateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer

Sapphire Biotech Files for Patent Protection and Tests 200 Bladder Cancer Patient Samples to Validate its Unique Biomarker to Detect Cancer

by admin | Feb 4, 2019 | Press

Sapphire began testing 200 bladder cancer patient samples to test for the presence of QSOX1-related biomarkers. Utilizing Sapphire’s proprietary antibodies to test the bladder cancer samples, Sapphire developed a prototype rapid diagnostic test that measures levels of...
Clinical Trial Begins Using Sapphire Biotech’s Lateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer

Sapphire Biotech, Inc. is Formed to Develop Novel Therapeutic Approaches for the Treatment of Cancer Metastasis

by admin | Jan 1, 2019 | Press

Sapphire Biotech’s technology was formed for the purpose of developing novel therapeutic approaches for the treatment of cancer metastasis. Sapphire has identified a novel compound, SBI-183, that selectively targets QSOX1, an enzyme important for tumor cell growth,...
Copyright 2020 Sapphire Biotech | Privacy Policy | Terms of Use